Co-directors of the Research Endometriosis (ROSE) Clinical Study, Drs. Peter Gregersen and Christine Metz, have been hard at work studying the cellular and genetic makeup of menstrual blood, or menstrual effluent (ME), and its potential to diagnose individuals who may have Endometriosis.
This condition occurs when tissues similar to the uterine lining begin to grow outside of the uterus creating lesions and even enveloping the fallopian tubes and ovaries. It affects 1 in every 10 females at reproductive age leaving them in often immense pain, infertility, and other medical complications. At this point in time, the only method for a definitive diagnosis is through invasive laparoscopic surgery.
This research being conducted is comparing both cellular and genetic differences between endometriosis patients and healthy controls to identify biomarkers that could be used for future approaches for diagnoses and even potential treatments. Single-cell-RNA-sequencing (-Seq) is being used to compare the endometrial tissue in collected ME from their participants in the study.
Millions of women suffer from this condition and these new understandings of endometriosis allows them to identify it earlier and enables them to get the medical attention they need. I look forward to seeing the rest of their results as they begin their new clinical trial comparing ME from women who have symptoms but have no diagnosis.